TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells

Medical Oncology

Volumn 32, Issue 10, 2015, Pages

  Wang, Xinfeng ^a   Wang, Jingjing ^a   Liu, Hong ^a   Xu, Ruirong ^a   Ding, Runsheng ^a   Jiang, Shenhua ^a   Wang, Xudong ^a   Huang, Hongming ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

BAFF; BLyS; Multiple myeloma; NF B; TRAF6

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TNFSF13B PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CASE REPORT; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA CELL LINE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; GENETIC TRANSFECTION; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; AGED; B-CELL ACTIVATING FACTOR; BLOTTING, WESTERN; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NF-KAPPA B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TRANSFECTION;

EID: 84940973379     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0671-2     Document Type: Article

References (24)

1. Demchenko YN, Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010;1:59–68.
2. Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB, et al. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. Clin Cancer Res. 2005;11:1974–82.
3. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci. 2002;115:679–88.
4. Ben-David D, Livne E, Reznick AZ. The involvement of oxidants and NF-kappaB in cytokine-induced MMP-9 synthesis by bone marrow-derived osteoprogenitor cells. Inflamm Res. 2012;61:673–88.
5. Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, et al. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Oncogene. 2006;25:6520–7.
6. Batten M, Fletcher C, Ng LG, Groom J, Wheway J, Laabi Y, et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol. 2004;172:812–22.
7. Jiang P, Yueguo W, Huiming H, Hongxiang Y, Mei W, Ju S. B-Lymphocyte stimulator: a new biomarker for multiple myeloma. Eur J Haematol. 2009;82:267–76.
8. Wang P, Qian L, Yuan X, Hu C, Wang L, Huang Q, et al. BlyS: a potential hallmark of multiple myeloma. Front Biosci. 2013;18:324–31.
9. Ju S, Wang Y, Ni H, Wang X, Jiang P, Kong X, et al. Correlation of expression levels of BLyS and its receptors with multiple myeloma. Clin Biochem. 2009;42:387–99.
10. Zhong L, Cao F, You Q. Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell. Tumour Biol. 2013;34:231–9.
11. Starczynowski DT, Lockwood WW, Delehouzee S, Chari R, Wegrzyn J, Fuller M, et al. TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest. 2011;121:4095–105.
12. Xiao N, Li H, Luo J, Wang R, Chen H, Chen J, et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFalpha-induced cancer cell migration. Biochem J. 2012;441:979–86.
13. Poblenz AT, Jacoby JJ, Singh S, Darnay BG. Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides. Biochem Biophys Res Commun. 2007;359:510–5.
14. Hongming H, Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res. 2009;33:115–22.
15. Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, et al. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk. 2012;12:155–63.
16. Romano A, Conticello C, Cavalli M. Immunological dysregulation in multiple myeloma microenvironment. Br J Haematol. 2014;2014:198539.
17. Arcipowski KM, Bishop GA. Roles of the kinase TAK1 in TRAF6-dependent signaling by CD40 and its oncogenic viral mimic, LMP1. PLoS One. 2012;7:e42478.
18. Wi SM, Moon G, Kim J, Kim ST, Shim JH, Chun E, et al. TAK1-ECSIT-TRAF6 complex plays a key role in the TLR4 signal to activate NF-kappaB. J Biol Chem. 2014;289:35205–14.
19. Xie P. TRAF molecules in cell signaling and in human diseases. J Mol Signal. 2013;8:7.
20. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–94.
21. Secreto F, Manske M, Price-Troska T, Ziesmer S, Hodge LS, Ansell SM, et al. B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells. Leuk Lymphoma. 2014;5:1884–92.
22. Shen X, Zhu W, Zhang X, Xu G, Ju S. A role of both NF-kappaB pathways in expression and transcription regulation of BAFF-R gene in multiple myeloma cells. Mol Cell Biochem. 2011;357:21–30.
23. Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Mol Cell Biochem. 2006;12:5887–94.
24. Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, Abouladze M, et al. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol. 2007;138:160–8.